Tardive dyskinesia syndromes: current concepts

https://doi.org/10.1016/S1353-8020(13)70028-2Get rights and content

Summary

Tardive syndromes (TS) encompass a broad spectrum of abnormal movements due to chronic exposure to dopamine receptor blocking agents. This review provides a compiled update on TS, including phenomenology, epidemiology, pathophysiology, genetic correlations and therapeutics, highlighting the emerging experience with atypical antipsychotics. The advent of atypical antipsychotics, which have lower affinity for dopamine receptors and act on 5-HT2A and 5-HT2C serotonin receptors, was expected to dramatically reduce the prevalence and incidence of this iatrogenic problem. Recent studies have shown that the reduction has been more modest than expected and TS remains an important challenge. Recent insights on pathophysiology, risk factors and genetic correlations have raised the hope for further individualized treatment for schizophrenic patients, and more strict use of antipsychotics. Up to now, there is no definite treatment for TS, but options range from relatively innocuous low doses of propranolol to more invasive procedures such as deep brain stimulation.

References (30)

  • HY Meltzer

    Update on typical and atypical antipsychotic drugs

    Annu Rev Med

    (2013)
  • CU Correll et al.

    Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

    Am J Psychiatry

    (2004)
  • AJM Loonen et al.

    New insights into the mechanism of drug-induced dyskinesia

    CNS Spectr

    (2012)
  • P Turrone et al.

    The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats

    Psychopharmacology (Berl)

    (2003)
  • S Silvestri et al.

    Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

    Psychopharmacology (Berl)

    (2000)
  • Cited by (87)

    • Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine

      2022, Parkinsonism and Related Disorders
      Citation Excerpt :

      Tardive dyskinesia (TD) is a potentially debilitating movement disorder that may be caused by exposure to dopamine-receptor antagonists (DRAs), including typical and atypical antipsychotics and antiemetics [1–3].

    • Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox

      2021, Sleep Medicine Clinics
      Citation Excerpt :

      Tardive akathisia is included in the tardive syndrome, a broad spectrum of DRBA-induced abnormal movements, which include tardive dyskinesia among other manifestations.5–7 The tardive syndrome has 2 main characteristics: it appears late after prolonged exposure to the DRBA, and it persists and continues, and often worsens, after the offending drug is withdrawn.6,7 Acute akathisia, on the other hand, is a condition with identical symptoms that tardive akathisia that occurs fairly early after the DRBA is introduced and dissipates upon its withdrawal.7

    • New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach

      2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry
      Citation Excerpt :

      Movement disorders, both acute and chronic, are well-described adverse effects of antipsychotic (AP) drugs and significantly affect patients' quality of life (Blanchet, 2003; Margolese et al., 2005; van Harten and Tenback, 2011). Tardive dyskinesia (TD) is a chronic, often irreversible, adverse effect of long-term AP medications treatment, and is characterized by repetitive and involuntary movement in the oral and facial regions, as well as the limbs and trunk (including tics, myoclonus and choreoathetosis) (Aquino and Lang, 2014; Casey, 2004; van Harten and Tenback, 2011; Zai et al., 2018). The course of TD may be fluctuating and the diagnosis is based on clinical evaluation (van Harten and Tenback, 2011).

    View all citing articles on Scopus
    View full text